



FACTS

FOUNDED
FEBRUARY 2006

LOCATION
VIENNA, AUSTRIA

STRATEGIC FOCUS
ANTIBACTERIAL TREATMENT OF RESISTANT INFECTIONS
IN THE COMMUNITY AND HOSPITAL SETTING

FINANCING
EUR 57 MILLION IN SERIES A

MAJOR SHAREHOLDERS
NOMURA PHASE4 VENTURES, HBM PARTNERS,
WELLCOME TRUST, GLS VENTURES,
NOVARTIS VENTURE FUND, SANDOZ GMBH

EXECUTIVE MANAGEMENT
DAVID CHISWELL, CEO
RODGER NOVAK, COO
RALF SCHMID, CFO
WILLIAM PRINCE, CMO

MORE INFORMATION

NABRIVA THERAPEUTICS AG
LEBERSTRASSE 20
1110 VIENNA, AUSTRIA
T +43 (0)1 74093 0
F +43 (0)1 74093 1900
OFFICE@NABRIVA.COM
WWW.NABRIVA.COM

CORPORATE OVERVIEW

Nabriva Therapeutics was founded in February 2006 as a spin-out of Sandoz GmbH raising Euro 42 Million in a Series A Financing Round. In October 2010 the company closed an additional Euro 15 Million financing. Both rounds were led by Nomura Phase4 Ventures and included all the Company's main shareholders Nomura Phase4 Ventures, HBM Partners, The Wellcome Trust, Global Life Science Ventures and Novartis Venture Fund. In addition, to the series A financing the company has also been awarded significant grants and loans from Austrian public institutions.

DRUG PORTFOLIO

Pleuromutilins are unique antibacterial compounds that interfere with bacterial protein synthesis via a specific interaction with the 23S rRNA of the 50S bacterial ribosome subunit and address the significant medical need for new antibiotic approaches to challenge serious infections in humans caused by multi-drug resistant bacteria.

Nabriva's lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia including those caused by MRSA and other antibiotic resistant bacteria. Extensive phase I data have demonstrated that BC-3781 can achieve therapeutically relevant blood and tissue levels in man with excellent tolerability when administered by either oral or intravenous routes.

Uncomplicated skin infections result in approximately 200 million physician visits per annum in the USA. The primary causative agent is *Staphylococcus aureus*, approximately 60% of which are MRSA strains. Nabriva Therapeutics' topical pleuromutilin (BC-7013) is active against MRSA and our clinical phase I studies have shown it to be safe, well tolerated and not systemically available when administered topically. Clinical phase II studies are planned to begin in 2010.

COMMERCIALIZATION STRATEGY

Nabriva Therapeutics holds unencumbered commercial rights to its compounds and will seek partners with significant commercial expertise in antibacterial therapies using the catalyst of data from the clinical phase II study in cSSSI.

FACTS

FOUNDED
FEBRUARY 2006

LOCATION
VIENNA, AUSTRIA

STRATEGIC FOCUS
ANTIBACTERIAL TREATMENT OF RESISTANT INFECTIONS
IN THE COMMUNITY AND HOSPITAL SETTING

FINANCING
EUR 57 MILLION IN SERIES A


MAJOR SHAREHOLDERS
NOMURA PHASE4 VENTURES, HBM PARTNERS,
WELLCOME TRUST, GLS VENTURES,
NOVARTIS VENTURE FUND, SANDOZ GMBH

EXECUTIVE MANAGEMENT
DAVID CHISWELL, CEO
RODGER NOVAK, COO
RALF SCHMID, CFO
WILLM PRINCE, CMO

MORE INFORMATION

NABRIVA THERAPEUTICS AG
LEBERSTRASSE 20
1110 VIENNA, AUSTRIA
T +43 (0)1 74093 0
F +43 (0)1 74093 1900
OFFICE@NABRIVA.COM
WWW.NABRIVA.COM

**COMPARATIVE ACTIVITY AGAINST MSSA
[n = 253] AND MRSA [n = 257]**



JMI LABORATORIES; STUDY WITH CLINICAL ISOLATES FROM 2006-2009

**DOSE-RESPONSE OF BC-3781, LINEZOLID AND VANCOMYCIN
IN THE MOUSE LUNG INFECTION MODEL OF MRSA**

